Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,732 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,051 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07750158 | Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease(STELLAR-316) | recruiting | Phase 3 | 600 | ExelixisINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07793695 | Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma(ZINC-1LT/IOHCC) | recruiting | Phase 2 | 60 | Anhui Provincial HospitalOTHER_GOV |
| 1 |
| Sep 21, 2026 |
| clinicaltrials |
| NCT07829874 | Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.(CASTLE-ZS-04) | not yet recruiting | Phase 2 | 180 | Fudan UniversityOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07829926 | Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer(LENTIG-HCC) | not yet recruiting | Phase 2 | 120 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT07830355 | Immunotherapy Plus Anlotinib After Surgery for Esophageal Squamous Cell Cancer With Residual Tumor and Positive Lymph Nodes | not yet recruiting | Phase 2 | 75 | Shanghai Chest HospitalOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT07830407 | Pre-Clinical Validation of ChemoINTEL Unified Algorithm Chemotherapeutic Response Prediction in Patients With Colorectal Cancer | recruiting | — | 100 | Pierian BiosciencesINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07830576 | Multimodal Survival Prediction Model for Colorectal Liver Metastases Post-Operation | recruiting | — | 205 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07830628 | Bile ctDNA Genomic Profiling and Concordance With Tumor Tissue in Biliary Tract Cancer | not yet recruiting | — | 100 | CHA UniversityOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831330 | Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer | not yet recruiting | Phase 2 | 59 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT07831993 | Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer | recruiting | Phase 2 | 54 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07832006 | Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 30 | Shunda DuOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT02221700 | Massage Therapy in Reducing Chemotherapy-Induced Peripheral Neuropathy in Patients With Gastrointestinal or Breast Malignancies | active not recruiting | N/A | 90 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT02874885 | Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer | active not recruiting | — | 341 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03776487 | Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer | active not recruiting | Phase 2 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03950609 | Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors | active not recruiting | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04234568 | Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors | active not recruiting | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04248582 | Cryotherapy for Locally Advanced Esophageal Cancer | active not recruiting | Phase 1 | 14 | Hunter Holmes Mcguire Veteran Affairs Medical CenterFED | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04291755 | Development and Analysis of a Stool Bank for Cancer Patients | enrolling by invitation | — | 100 | Persephone BiosciencesINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04593407 | Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for Colorectal Laterally Spreading Lesions.(intERsection) | active not recruiting | N/A | 236 | José Carlos Marín GabrielOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05141513 | Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma | active not recruiting | Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05863052 | Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population | active not recruiting | — | 72 | University of OklahomaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06271941 | Reducing Neoplasia Recurrence After Endoscopic Resection of Large Colorectal Polyps(ABLATION) | recruiting | N/A | 892 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06954116 | Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence(CCGLC-017) | recruiting | Phase 2 | 26 | Tongji HospitalOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07147361 | Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma(PB-PD1R-SCC) | active not recruiting | — | 800 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07435038 | Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 120 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT07450859 | A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | recruiting | Phase 2 | 39 | BicycleTx LimitedINDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT07627191 | GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer | recruiting | Early Phase 1 | 30 | University of ArizonaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07676383 | Precision Navigation to Improve Community Cancer Screening Participation | recruiting | N/A | 1,500 | Hunan Cancer HospitalOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07705334 | A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors(Luca-1) | recruiting | Phase 1 | 30 | SHY TherapeuticsINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07827053 | Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer | not yet recruiting | Phase 2 | 36 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Sep 18, 2026 | clinicaltrials |
| NCT07827807 | PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCC(Pearl) | not yet recruiting | Phase 2 | 40 | Chang Gung Memorial HospitalOTHER | 0 | Sep 18, 2026 | clinicaltrials |
| NCT07827911 | Predicting Pancreatic Fistula After Pancreatic Surgery Using Preoperative Immunity | not yet recruiting | — | 310 | Institut Paoli-CalmettesOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07828236 | PHASE 1 TRIAL OF Lm-LLO-TT AND GEMCITABINE IN UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA | not yet recruiting | Phase 1 | 18 | Loki Therapeutics, Inc.INDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07828756 | Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer | not yet recruiting | Phase 2 | 147 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07828899 | Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer | not yet recruiting | N/A | 212 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07829081 | Research on Effective Strategies After Immunotherapy for Mismatch Repair-deficient Early-stage GI Tumors(RESIST) | recruiting | — | 234 | University Hospital, Basel, SwitzerlandOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07829185 | Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer(FALCON) | not yet recruiting | Phase 1 | 30 | University of OklahomaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT02851784 | Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma | recruiting | Phase 2 / Phase 3 | 80 | Chinese PLA General HospitalOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04152499 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)(MK-2870-001) | active not recruiting | Phase 1 / Phase 2 | 1,410 | Klus Pharma Inc.INDUSTRY | 6 | Sep 17, 2026 | clinicaltrials |
| NCT04409340 | Viscoelasticity Imaging to Assess Liver Cancer(VisCan) | recruiting | — | 200 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05043688 | Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. | active not recruiting | Phase 3 | 426 | Zhigang LiOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06275737 | POP-UP: a Single-arm, Two-cohort Study: an 8-week Trimodal Pre-habilitation Program for Patients With Pancreatic Ductal Adenocarcinoma and Oesogastric(POP-UP) | recruiting | N/A | 72 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06361888 | A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer | recruiting | Phase 2 / Phase 3 | 502 | HutchmedINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06462183 | Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) | active not recruiting | Phase 1 | 105 | Rgenta Therapeutics IncINDUSTRY | 2 | Sep 17, 2026 | clinicaltrials |
| NCT06529523 | Tislelizumab in People With Colorectal Cancer | recruiting | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Sep 17, 2026 | clinicaltrials |
| NCT06531408 | Predicting Incidental Gallbladder Cancer(P-iGBC) | active not recruiting | — | 30,000 | University Hospital Plymouth NHS TrustOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06645015 | The AIDPRO-CRC Trial(AIDPRO-CRC) | recruiting | N/A | 1,200 | Zealand University HospitalOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06780111 | Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) | recruiting | Phase 1 / Phase 2 | 298 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Sep 17, 2026 | clinicaltrials |
| NCT07020117 | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | recruiting | Phase 1 | 150 | Aktis Oncology, Inc.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07027436 | Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.(DARTS) | recruiting | Phase 3 | 30 | Hamilton Health Sciences CorporationOTHER | 1 | Sep 17, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 21, 2026source: clinicaltrials